Corrigendum to "On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II" [Molecular Genetics and Metabolism Volume 141, Issue 3 (2024) 108143]

Mol Genet Metab. 2024 Mar;141(3):108344. doi: 10.1016/j.ymgme.2024.108344. Epub 2024 Feb 9.

Authors

Y Sato¹, P Yoshida², T Yamamoto², S So², K Tanizawa²

Affiliations

¹ JCR Pharmaceuticals, Hyogo, Japan. Electronic address: sato-yuji@jp.jcrpharm.com.
² JCR Pharmaceuticals, Hyogo, Japan.

PMID: 38341365
DOI: 10.1016/j.ymgme.2024.108344

No abstract available

Publication types

Published Erratum